Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus ICE versus ICE for relapsed or refractory non-GCB diffuse large B-cell lymphoma
ChiCTR1900022909Phase 3Not yet recruiting
- Sponsor
- Union Hospital
- Start
- May 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenalidomide, ifosfamide, carboplatin and etoposide in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Union Hospital. Primary endpoints: overall response rate, complete response rate and 3 more. Planned start May 2019; status: not yet recruiting.
02
Drugs
lenalidomideifosfamidecarboplatinetoposide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR1900022909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022909.